[go: up one dir, main page]

WO2006067224A3 - Nouveaux composes - Google Patents

Nouveaux composes Download PDF

Info

Publication number
WO2006067224A3
WO2006067224A3 PCT/EP2005/057132 EP2005057132W WO2006067224A3 WO 2006067224 A3 WO2006067224 A3 WO 2006067224A3 EP 2005057132 W EP2005057132 W EP 2005057132W WO 2006067224 A3 WO2006067224 A3 WO 2006067224A3
Authority
WO
WIPO (PCT)
Prior art keywords
spiro
compounds
benzodioxole
receptor antagonists
disorders
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2005/057132
Other languages
English (en)
Other versions
WO2006067224A2 (fr
Inventor
Emma Barker
Jensen Annika Jenmalm
Erik Nordling
Andrew Proud
Martin Slater
Mikael Weber
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Swedish Orphan Biovitrum AB
Original Assignee
Biovitrum AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from SE0403160A external-priority patent/SE0403160D0/sv
Application filed by Biovitrum AB filed Critical Biovitrum AB
Publication of WO2006067224A2 publication Critical patent/WO2006067224A2/fr
Publication of WO2006067224A3 publication Critical patent/WO2006067224A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/10—Spiro-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

L'invention concerne des composés de formule (I) dans laquelle R1, A, Y, n et m ont la signification indiquée dans la description, des procédés de préparation desdits composés, des compositions pharmaceutiques les comprenant, et l'utilisation desdits composés et compositions dans la prophylaxie ou le traitement de troubles associés au récepteur de l'orexine 1 et de troubles associés au récepteur de l'orexine 2. A titre d'exemples pour lesdits troubles, on peut citer l'obésité et les troubles associés de type diabète de type II, la dyslipidémie et le syndrome métabolique, les maladies cardiovasculaires de type maladie vasculaire athéroscléreuse, angine de poitrine, infarctus du myocarde et AVC, la toxicomanie, et les troubles du sommeil.
PCT/EP2005/057132 2004-12-23 2005-12-22 Nouveaux composes Ceased WO2006067224A2 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
SE0403160A SE0403160D0 (sv) 2004-12-23 2004-12-23 New compounds
SE0403160-5 2004-12-23
US65380305P 2005-02-17 2005-02-17
US60/653,803 2005-02-17

Publications (2)

Publication Number Publication Date
WO2006067224A2 WO2006067224A2 (fr) 2006-06-29
WO2006067224A3 true WO2006067224A3 (fr) 2006-11-02

Family

ID=36602122

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2005/057132 Ceased WO2006067224A2 (fr) 2004-12-23 2005-12-22 Nouveaux composes

Country Status (1)

Country Link
WO (1) WO2006067224A2 (fr)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008008517A2 (fr) 2006-07-14 2008-01-17 Merck & Co., Inc. Diazépans pontés antagonistes du récepteur de l'oréxine
CA2666193A1 (fr) 2006-08-08 2008-02-14 Sanofi-Aventis Imidazolidin-2,4-dione arylaminoaryl-alkyl-substituee, son procede de fabrication, medicament contenant ce compose et son utilisation
PE20081229A1 (es) 2006-12-01 2008-08-28 Merck & Co Inc Antagonistas de receptor de orexina de diazepam sustituido
JP4881476B2 (ja) 2007-05-23 2012-02-22 メルク・シャープ・エンド・ドーム・コーポレイション ピリジルピペリジン・オレキシン受容体アンタゴニスト
WO2008150364A1 (fr) 2007-05-23 2008-12-11 Merck & Co., Inc. Antagonistes du récepteur de la cyclopropylpyrrolidine orexine
EP2025674A1 (fr) 2007-08-15 2009-02-18 sanofi-aventis Tetrahydronaphthaline substituée, son procédé de fabrication et son utilisation en tant que médicament
UY31968A (es) 2008-07-09 2010-01-29 Sanofi Aventis Nuevos derivados heterocíclicos, sus procesos para su preparación, y sus usos terapéuticos
WO2010043592A1 (fr) * 2008-10-15 2010-04-22 Revotar Biopharmaceuticals Ag Inhibiteurs de la lipase destinés à être utilisés dans le traitement de l’obésité
US8957219B2 (en) 2008-10-17 2015-02-17 Shionogi & Co., Ltd. Acetic acid amide derivative having inhibitory activity on endothelial lipase
WO2010068601A1 (fr) 2008-12-08 2010-06-17 Sanofi-Aventis Hydrate de fluoroglycoside hétéroaromatique cristallin, ses procédés de fabrication, ses procédés d'utilisation et compositions pharmaceutiques le contenant
MX2012001729A (es) 2009-08-26 2012-06-13 Sanofi Sa Nuevos hidratos cristalinos de fluoroglicosido heteroaromatico, productos farmaceuticos que comprenden estos compuestos, y su empleo.
GB201021104D0 (en) * 2010-12-13 2011-01-26 Univ Leuven Kath Novel compounds for the treatment of neurodegenerative diseases
US8895547B2 (en) 2011-03-08 2014-11-25 Sanofi Substituted phenyl-oxathiazine derivatives, method for producing them, drugs containing said compounds and the use thereof
WO2012120051A1 (fr) 2011-03-08 2012-09-13 Sanofi Dérivés benzyl-oxathiazine substitués avec adamantane ou noradamantane, médicaments contenant ces composés et leur utilisation
EP2683702B1 (fr) 2011-03-08 2014-12-24 Sanofi Nouveaux dérivés de phényle-oxathiazine substitués, leur procédé de fabrication, médicament contenant ces liaisons et son utilisation
WO2012120052A1 (fr) 2011-03-08 2012-09-13 Sanofi Dérivés d'oxathiazine substitués par des carbocycles ou des hétérocycles, leur procédé de préparation, médicaments contenant ces composés et leur utilisation
WO2012120053A1 (fr) 2011-03-08 2012-09-13 Sanofi Dérivés oxathiazine ramifiés, procédé pour leur préparation, utilisation en tant que médicament, agents pharmaceutiques contenant ces dérivés et leur utilisation
EP2683700B1 (fr) 2011-03-08 2015-02-18 Sanofi Dérivés d'oxathiazine tétra-substitués, leur procédé de fabrication, leur utilisation comme médicament ainsi que médicaments en étant pourvu et leur utilisation
US8710050B2 (en) 2011-03-08 2014-04-29 Sanofi Di and tri- substituted oxathiazine derivatives, method for the production, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
US8828994B2 (en) 2011-03-08 2014-09-09 Sanofi Di- and tri-substituted oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
WO2012120058A1 (fr) 2011-03-08 2012-09-13 Sanofi Dérivés d'oxathiazine substitués par des groupes benzyle ou hétérométhylène, leur procédé de production, leur utilisation comme médicament ainsi que produits pharmaceutiques les contenant et leur utilisation
AR088352A1 (es) 2011-10-19 2014-05-28 Merck Sharp & Dohme Antagonistas del receptor de 2-piridiloxi-4-nitrilo orexina
SG11201404738QA (en) 2012-02-07 2014-10-30 Eolas Therapeutics Inc Substituted prolines / piperidines as orexin receptor antagonists
US9440982B2 (en) 2012-02-07 2016-09-13 Eolas Therapeutics, Inc. Substituted prolines/piperidines as orexin receptor antagonists
UY36272A (es) 2014-08-13 2016-02-29 Eolas Therapeutics Inc Difluoropirrolidinas como moduladores de los receptores de orexinas
JP6883045B2 (ja) 2016-02-12 2021-06-02 アストラゼネカ・アクチエボラーグＡｓｔｒａｚｅｎｅｃａ Ａｋｔｉｅｂｏｌａｇ オレキシン受容体調節因子としてのハロ置換ピペリジン
EP3454857A1 (fr) 2016-05-10 2019-03-20 INSERM (Institut National de la Santé et de la Recherche Médicale) Méthodes et compositions pharmaceutiques pour le traitement de maladies inflammatoires auto-immunes

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004052876A1 (fr) * 2002-12-12 2004-06-24 Janssen Pharmaceutica, N.V. 4-phenyl-[1,3]-dioxanes substitues
WO2004111056A2 (fr) * 2003-06-13 2004-12-23 Biofocus Plc Banques de composes

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004052876A1 (fr) * 2002-12-12 2004-06-24 Janssen Pharmaceutica, N.V. 4-phenyl-[1,3]-dioxanes substitues
WO2004111056A2 (fr) * 2003-06-13 2004-12-23 Biofocus Plc Banques de composes

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
PORTER R A ET AL: "1,3-Biarylureas as selective non-peptide antagonists of the orexin-1 receptor", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, OXFORD, GB, vol. 11, 2001, pages 1907 - 1910, XP002269254, ISSN: 0960-894X *
PUJOL MD ROSELL G GUILLAUMET G: "Novel tricyclic spiropiperidines. Synthesis and adrenergic activity of spiro[1,3-benzodioxolopiperidines] and spiro[1,3-benzodioxanepiperidines", EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, EDITIONS SCIENTIFIQUE ELSEVIER, PARIS, FR, vol. 31, no. 11, 1996, pages 889 - 894, XP004063481, ISSN: 0223-5234 *
SAKURAI T ET AL: "OREXINS AND OREXIN RECEPTORS: A FAMILY OF HYPOTHALAMIC NEUROPEPTIDES AND G PROTEIN-COUPLED RECEPTORS THAT REGULATE FEEDINGBEHAVIOR", CELL, CELL PRESS, CAMBRIDGE, NA, US, vol. 92, 20 February 1998 (1998-02-20), pages 573 - 585, XP002943277, ISSN: 0092-8674 *
SANCHEZ I ET AL: "SYNTHESIS OF NEW PIPERIDINE AND CYCLOHEXYLAMINO-SPIRO DERIVATIVES AS POTENTIAL ANTICALCIUM AGENTS", SCIENTIA PHARMACEUTICA, OESTERREICHISCHE APOTHEKER VERLAGSGESELLSCHAFT,, AT, vol. 70, no. 2, 2002, pages 177 - 187, XP009035726, ISSN: 0036-8709 *

Also Published As

Publication number Publication date
WO2006067224A2 (fr) 2006-06-29

Similar Documents

Publication Publication Date Title
WO2006067224A3 (fr) Nouveaux composes
HK1054333A1 (zh) 杂芳基脲神经肽yy5受体拮抗剂
CL2007002347A1 (es) Compuestos derivados de fenilo, piridina y quinolina; procedimiento de preparacion; composicion farmaceutica; y uso del compuesto en el tratamiento de diabetes mellitus, trastornos en la tolerancia de la glucosa, obesidad, enfermedad de crohn, enferm
WO2010036613A8 (fr) Nouveaux dérivés de benzimidazole cycliques utiles en tant qu'agents anti-diabétiques
NO20084318L (no) Inhibitorer av II-beta-hydroksystereoid dehydrogenase I
WO2007127763A3 (fr) Inhibiteurs de 11-bêta-hydroxystéroïde déshydrogénase 1
NO20084403L (no) Cykloheksylpyrazol-lactamderivater som inhibitorer av II-beta-hydroksysteroid dehydrogenase I
NZ592723A (en) Cyclic pyrimidin-4-carboxamides as ccr2 receptor antagonists for treatment of inflammation, asthma and copd
DE602007004324D1 (en) 11-beta-hydroxysteroid-dehydrogenase-1-hemmer
WO2009042922A3 (fr) Conjugués inhibiteurs de peptide/peptidase et leurs procédés de fabrication et d'utilisation
WO2004052370A3 (fr) Utilisation de composes de la quinoline pour traiter des troubles lies au recepteur mch
CY1112398T1 (el) Πυρρολιδινονες υποκατασταθεισες απο κυκλοεξυλιο ως αναστολεις της 11-β-υδροξυστεροειδικης αφυδρογονασης 1
WO2004005262A3 (fr) Nouveaux antagonistes des recepteurs du neuropeptide y y5
WO2007150016A3 (fr) Antagoniste du récepteur il-8
WO2008021560A3 (fr) Analogue du gip et polypeptides hybrides possédant des propriétés sélectives
WO2008081399A3 (fr) Dérivés 2-aza-bicyclo[3.1.0]hexane
CL2007001597A1 (es) Compuestos derivados de 2-oxo-piridin-1(2h)-il-tiazol, imidazol o tiofen-carboxamida; composicion farmaceutica; y uso para el tratamiento de una enfermedad mediada por la estearoil-coa-desaturasa, tal como sindrome metabolico, hipertension y diabetes
WO2008018827A8 (fr) Dérivés de benzimidazole utilisables pour le traitement des troubles liés au récepteur des vallinoïdes trpvl
WO2007120270A3 (fr) Antagonistes de récepteur du glucagon, procédés de préparation et utilisations thérapeutiques
WO2005123718A3 (fr) Derives de benzimidazolone d'acide carboxylique
WO2007120284A3 (fr) Antagonistes de récepteur du glucagon, procédés de préparation et utilisations thérapeutiques
NO20080291L (no) Indol-3-yl-karbonyl-piperidin-benzomidazolderivater som Via reseptorantagonister
WO2006102112A3 (fr) Recepteur 1 de prokineticine
WO2007144768A3 (fr) Utilisation d'agonistes du récepteur de la vasopressine peptidiques
EA201000926A1 (ru) Пиперазины в качестве агентов против ожирения

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KN KP KR KZ LC LK LR LS LT LU LV LY MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 05823819

Country of ref document: EP

Kind code of ref document: A2